Get started
Kiniksa Pharmaceuticals International, plcKiniksa Pharmaceuticals International, plcKiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsSeasonalsOptionsETFs
Full chart
Full chart

Compare with Kiniksa Pharmaceuticals International, plc



Key facts today


Kiniksa (KNSA) posted record Q2 revenue and raised 2026 guidance, citing ARCALYST market expansion and untapped potential; pipeline progress for KPL-387 and KPL-1161 backed by positive clinical data. 1
Analyze the impactAnalyze the impact

Key stats


Market capitalization
‪6.01 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
78.38
Basic EPS (TTM)
1.06 USD
Net income (FY)
‪59.01 M‬ USD
Revenue (FY)
‪677.56 M‬ USD
Shares float
‪45.02 M‬
Beta (1Y)
0.09

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Employees


Employees (FY)
366
Change (1Y)
+51+16.19%
Revenue / Employee (1Y)
‪1.85 M‬ USD
Net income / Employee (1Y)
‪161.22 K‬ USD

Company info


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Sanj K. Patel
Website
kiniksa.com
Headquarters
London
Founded
2024
IPO date
May 24, 2018
ISIN
GB00BRXB0C07
FIGI
BBG00KT2KFX7
Identifiers
ISIN GB00BRXB0C07
CFI code
ESVUFR
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock


IWM
iShares Russell 2000 Index Fund
Weight0.11%
Market value‪84.58 M‬
VBK
Vanguard Morningstar Small-Cap Growth ETF
Weight0.09%
Market value‪41.14 M‬
IWO
iShares Russell 2000 Growth Fund
Weight0.22%
Market value‪31.21 M‬
VTWO
Vanguard Russell 2000 ETF
Weight0.10%
Market value‪17.68 M‬
DFAS
Dimensional U.S. Small Cap ETF
Weight0.07%
Market value‪11.62 M‬
XSPU
Xtrackers S&P 500 SWAP UCITS ETF Capitalisation 1C
Weight0.11%
Market value‪10.81 M‬
XSXD
Xtrackers S&P 500 Swap UCITS ETF
Weight0.11%
Market value‪10.81 M‬
XS5G
Xtrackers S&P 500 Swap UCITS ETF
Weight0.11%
Market value‪10.81 M‬
XS5E
Xtrackers S&P 500 Swap UCITS ETF 5C-EUR Hedged
Weight0.11%
Market value‪10.81 M‬
DFMC
U.S. Micro Cap Portfolio: ETF Class Shares
Weight0.10%
Market value‪9.35 M‬
VHT
Vanguard Health Care ETF
Weight0.04%
Market value‪8.28 M‬

Explore more ETFs 

Frequently asked questions


The current price of KNSA is 77.15 USD — it has increased by 1.85% in the past 24 hours. Watch Kiniksa Pharmaceuticals International, plc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Kiniksa Pharmaceuticals International, plc stocks are traded under the ticker KNSA.
KNSA stock has fallen by −1.27% compared to the previous week, the month change is a 3.25% rise, over the last year Kiniksa Pharmaceuticals International, plc has showed a 109.08% increase.
We've gathered analysts' opinions on Kiniksa Pharmaceuticals International, plc future price: according to them, KNSA price has a max estimate of 108.00 USD and a min estimate of 87.00 USD. Watch KNSA chart and read a more detailed Kiniksa Pharmaceuticals International, plc stock forecast: see what analysts think of Kiniksa Pharmaceuticals International, plc and suggest that you do with its stocks.
KNSA reached its all-time high on Jul 29, 2026 with the price of 82.94 USD, and its all-time low was 5.01 USD and was reached on Oct 17, 2019. View more price dynamics on KNSA chart.
See other stocks reaching their highest and lowest prices.
KNSA stock is 1.78% volatile and has beta coefficient of 0.09. Track Kiniksa Pharmaceuticals International, plc stock price on the chart and check out the list of the most volatile stocks — is Kiniksa Pharmaceuticals International, plc there?
Today Kiniksa Pharmaceuticals International, plc has the market capitalization of ‪6.13 B‬, it has increased by 0.11% over the last week.
Yes, you can track Kiniksa Pharmaceuticals International, plc financials in yearly and quarterly reports right on TradingView.
Kiniksa Pharmaceuticals International, plc is going to release the next earnings report on Nov 3, 2026. Keep track of upcoming events with our Earnings Calendar.
KNSA earnings for the last quarter are 0.30 USD per share, whereas the estimation was 0.30 USD resulting in a 0.18% surprise. The estimated earnings for the next quarter are 0.37 USD per share. See more details about Kiniksa Pharmaceuticals International, plc earnings.
Kiniksa Pharmaceuticals International, plc revenue for the last quarter amounts to ‪243.60 M‬ USD, despite the estimated figure of ‪226.49 M‬ USD. In the next quarter, revenue is expected to reach ‪259.65 M‬ USD.
KNSA net income for the last quarter is ‪25.43 M‬ USD, while the quarter before that showed ‪22.59 M‬ USD of net income which accounts for 0.00% change. Track more Kiniksa Pharmaceuticals International, plc financial stats to get the full picture.
No, KNSA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 10, 2026, the company has 366 employees. See our rating of the largest employees — is Kiniksa Pharmaceuticals International, plc on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Kiniksa Pharmaceuticals International, plc EBITDA is ‪102.04 M‬ USD, and current EBITDA margin is 11.63%. See more stats in Kiniksa Pharmaceuticals International, plc financial statements.
Like other stocks, KNSA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Kiniksa Pharmaceuticals International, plc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Kiniksa Pharmaceuticals International, plc technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Kiniksa Pharmaceuticals International, plc stock shows the buy signal. See more of Kiniksa Pharmaceuticals International, plc technicals for a more comprehensive analysis.